sanofi
Sarclisa Gains FDA Approval as First-Line Treatment for Newly Diagnosed Multiple Myeloma
Sarclisa, FDA approval, first-line treatment, multiple myeloma, Sanofi, isatuximab, VRd combination therapy.
Sanofi Prepares for Regulatory Submission of Tolebrutinib in Non-Relapsing Secondary Progressive Multiple Sclerosis
Tolebrutinib, BTK inhibitor, Multiple sclerosis, Non-relapsing secondary progressive multiple sclerosis (nrSPMS), Sanofi, HERCULES study, GEMINI 1 and 2 studies, Regulatory approval
Enhanced Manufacturing Efforts by Sanofi and AstraZeneca Aim to Prevent Beyfortus Shortfalls in 2024
Beyfortus, RSV prevention, monoclonal antibody, Sanofi, AstraZeneca, manufacturing efforts, supply chain management
Sanofi’s $1 Billion Bet on Muscular Dystrophy Drug Falters, Fulcrum Shares Plummet
Sanofi, Fulcrum, muscular dystrophy drug, pharmaceutical failure, stock market impact
Sanofi Enters Radiopharmaceutical Market with $110M Licensing Deal for AlphaMedix, Challenging Novartis’ Dominance
Sanofi, radiopharmaceuticals, radioligand therapy, AlphaMedix, Novartis, neuroendocrine tumors, cancer treatment, pharmaceutical industry
Sanofi Enters Radiopharmaceutical Market with $110 Million Licensing Agreement
Sanofi, Radiopharmaceuticals, Licensing Deal, RadioMedix, Orano Med, AlphaMedix, Neuroendocrine Tumors
Sanofi’s Tolebrutinib Shows Mixed Results in Phase 3 MS Trials, Plans for FDA Filing Remain
Tolebrutinib, Sanofi, Multiple Sclerosis, Phase 3 Trials, FDA Filing
Sanofi’s Tolebrutinib Shows Mixed Results in Multiple Sclerosis Trials
Sanofi, Tolebrutinib, Multiple Sclerosis, BTK Inhibitor, Clinical Trials
Vir Biotechnology Acquires T-Cell Engagers from Sanofi, Reduces Staff by 25% in Strategic Pipeline Shift
Vir Biotechnology, Sanofi, T-cell engagers, pipeline switch-up, staff reduction, biotech industry, pharmaceuticals
Vir Biotechnology Lays Off 25% of Staff, Shifts Focus to Cancer Research in Sanofi Partnership
Vir Biotechnology, layoffs, Sanofi partnership, cancer research, monoclonal antibodies